Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pending EU Approval Of Eloctate, Sobi Opts In To Second Hemophilia Program With Biogen

This article was originally published in The Pink Sheet Daily

Executive Summary

Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.

Advertisement

Related Content

Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix
Auxilium Signs Sobi As Pfizer Replacement In Europe

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel